Advancements in Lymphoma and Leukaemia – an expert view

17:30 – 20:30
Tuesday 9th October 2018
The Terrace Suite, Miskin Manor, Cardiff

‘Advancements in Lymphoma and Leukemia – a expert view’ is an evening medical education meeting in lymphoid malignancies focusing on Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL). The meeting will bring together a notable faculty of oncology experts from across the UK who will preview the latest advances in research, consider the likely impact on the clinic of tomorrow, and discuss and debate the pertinent issues which are affecting the professional community. The meeting offers you and the audience the opportunity to discuss with peers and experts the latest scientific data likely to shape the treatment paradigms in these respective fields.



Professor Christopher FeganProfessor Christopher Fegan
Consultant Haematologist,
University Hospital of Wales

The full programme can be viewed HERE

Who should attend?
This meeting is ideal for:

  • Consultants
  • GPs
  • Pharmacists
  • Nurses
  • Researchers and
  • Scientists

and any healthcare professionals who have an interest in the future shape and direction of FL & CLL research and treatment.

‘Advancements in Lymphoma and Leukaemia – an expert view’ (code: 121975) has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 2 category 1 (external) CPD credit(s). Please note, CPD credits obtained through RCP will be accepted by other medical colleges such as the Royal College of Pathologists and the Royal College of Nursing.

When & Where
Tuesday 9th October 2018, 17:30 – 20:30
Miskin Manor Hotel
Talbot Green,
CF72 8ND.
Map here

The meeting costs are underwritten by Gilead Sciences Ltd. and the event is free of charge for healthcare professionals to attend. Places are strictly limited by room capacity.

Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.